NCT00258180View on ClinicalTrials.gov

Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 15, 2005

Primary Completion Date

February 24, 2009

Study Completion Date

February 24, 2009

Conditions
DiarrheaGastrointestinal ComplicationsUnspecified Childhood Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

filgrastim

Administered IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover

DRUG

cyclophosphamide

Administered IV over 1 hour on days 1-4

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Johns Hopkins University

OTHER

NCT00258180 - Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy | Biotech Hunter | Biotech Hunter